PapersPMID:17072885
The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
- findings
- 7
- compound
- 1
- endpoints
- 7
- Study, every finding
- RCT
- Dose studied, every finding
- silymarin 200 mg tablet three times daily for 4 months
- Population, every finding
- adults with type II diabetes, conventional therapy continued in both arms
What moved
How to read these marks →“The results showed a significant decrease in HbA(1)c, FBS, total cholesterol, LDL, triglyceride SGOT and SGPT levels in silymarin treated patients compared with placebo as well as with values at the beginning of the study in each group.”
- Decreases glycated haemoglobin (HbA1c)
very limited
- Decreases fasting blood glucose
very limited
- Decreases total cholesterol (TC)
very limited
- Decreases LDL cholesterol
very limited
- Decreases triglycerides
very limited
- Decreases aspartate aminotransferase
very limited
- Decreases alanine aminotransferase
very limited
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- type II diabetic patients on conventional therapy
- Participants
- 51
- Comparator
- placebo
- Duration
- 122 days
- Endpoints measured
- 14